Month: June 2021

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ® (umbralisib), the Company’s once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsed/refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress. The data presented today were previously presented at the American Society of Clinical Oncology (ASCO) annual meeting. PRESENTATION HIGHLIGHTS: Poster Presentation Title:...

Figure 1Location of the Algarrobo IOCG Project.Figure 2Magnetic survey coverage of the Algarrobo ProjectFigure 3Strongly mineralized intercepts from the newly discovered Gloria mineralized trend (assays pending)TORONTO, June 11, 2021 (GLOBE NEWSWIRE) — Nobel29 Resources Corp. (TSX-V: NBLC) (the “Company” or “Nobel”) provides an update on the ongoing exploration program at the Algarrobo project in Chile (Figure 1) (the “Project” or the “Algarrobo Project”). The Company has completed 31 diamond drill holes to date, for which it has assays results for 12 drill holes on wide spaced target areas within the Algarrobo Project. In addition, the Company has received interpreted results for 3,733 line km of high-resolution magnetic survey data covering the Project, and this data indicates...

Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical advancement of itolizumab in first-line treatment of aGVHD Conference call today at 8:00 am eastern time LA JOLLA, Calif., June 11, 2021 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Phase 1b EQUATE study in first-line acute graft-versus-host-disease (aGVHD). The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids. There are no approved treatments for this severe, life threatening...

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade Cytokine Release Syndrome observed Durability of response in ALL patients continues to support potential for transformational therapy in adult ALL Conference Call to be held on Friday, June 11, 2021 at 8:30 am ET / 1:30 pm BST LONDON, June 11, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a poster presentation related to AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and included an update of duration of response in r/r adult Acute Lymphoblastic Leukemia...

TORONTO, June 11, 2021 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ: EGLX) (TSX: EGLX), a media and content platform for video game and esports fans to connect and engage, is pleased to announce that the Company has priced the offering (the “Offering”) at USD$5.75 per common share (the “Common Shares”) for aggregate gross proceeds to the Company of USD$46,000,000. In connection with the offering the Company has entered into an agreement with a syndicate of underwriters co-led by RBC Capital Markets and Canaccord Genuity (the “Lead Underwriters”) as joint lead bookrunning managers, with B. Riley Securities acting as joint bookrunner, and including Paradigm Capital Inc., Scotia Capital Inc., Alliance Global Partners, Colliers Securities LLC and Haywood Securities Inc., as co-managers...

Tryg announces today that Scandi JV Co 2 A/S (a company owned 50/50 by Tryg A/S and the Intact group) has entered into a conditional share purchase agreement for the sale of Codan’s Danish business (“Codan Denmark”) to Alm. Brand A/S. The agreed cash purchase price is approximately DKK 12.6bn for 100% of the share capital of Codan Denmark. Tryg will receive 50% of the sale proceeds. The sale is expected to have a positive impact on Tryg’s previously disclosed expectation of an ROI of approximately 7% for the acquisition of RSA. The transaction is subject to, e.g., customary regulatory approvals from relevant authorities – including from the Danish Financial Supervisory Authority and the competition authorities – and completion by Alm. Brand A/S of an underwritten rights issue that is also supported by Alm....

ST. LOUIS, June 11, 2021 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced that CFO & COO Tamar Rapaport-Dagim will speak at the 44th Nasdaq Investor Conference on June 15 at 7:00 am ET. The live webcast is available at https://investors.amdocs.com/ and a replay will be available at the same address. Supporting ResourcesLearn more about Amdocs Investor Relations Keep up with Amdocs news by visiting the company’s website Subscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTubeAbout AmdocsAmdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 27,000 employees partner with the leading players in the communications and media...

Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior RUBY trial of EDIT-301 for sickle cell disease active and recruiting CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data supporting the initiation of the EDIT-301 Phase 1/2 RUBY clinical trial to evaluate EDIT-301, a one-time, durable, autologous cell therapy medicine to treat sickle cell disease. EDIT-301 is the first experimental medicine generated using CRISPR/Cas12a gene editing. The Company reported the data in an oral presentation at the 26th Congress of the European Hematology Association (EHA) being held virtually. In these...

ST. JOHN’S, Newfoundland and Labrador, June 11, 2021 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF), Canada’s Ocean Company, is pleased to announce that its wholly owned subsidiary, Kraken Robotic Systems Inc, has signed a Cooperative Research and Development Agreement (CRADA) with Naval Surface Warfare Center, Carderock Division (NSWCCD). Under the CRADA, the Battery Certification and Integration Branch, Code 636 of NSWC Carderock, will test Kraken’s pressure tolerant lithium-ion batteries. The testing is expected to take four months to complete and is expected to start in calendar Q3 of this year. Kraken Comments“We are excited to enter into a CRADA with NSWC Carderock,” said Kraken President & CEO, Karl Kenny. “Since 2018, we have delivered our 6000-meter pressure tolerant batteries to several US and...